Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study.
Human Endogenous Retrovirus K(HML-2) Gag and Env specific T-cell responses are not detected in HTLV-I-infected subjects using standard peptide screening methods.
Dilantin (phenytoin) Supplemental Approval Letter
Correction: quantitative detection of epstein-barr virus DNA in cerebrospinal fluid and blood samples of patients with relapsing-remitting multiple sclerosis.
Multiple sclerosis: Cognitive status declines on warmer days in patients with multiple sclerosis.
Survey results show that adults are willing to pay higher insurance premiums for generous coverage of specialty drugs.
Interferon Beta-1a (AVONEX®) as a Treatment Option for Untreated Patients with Multiple Sclerosis (AXIOM): A Prospective, Observational Study.
Non-steroidal anti-inflammatory drug indometacin enhances endogenous remyelination.
Age-specific sex ratio of multiple sclerosis in the National Swedish MS Register (SMSreg).
Secukinumab shines in small MS trial
Monitoring the John Cunningham virus throughout natalizumab treatment in multiple sclerosis patients.
Psychiatric disorders in patients with multiple sclerosis.
A2A Adenosine Receptor Signaling in Lymphocytes and the Central Nervous System Regulates Inflammation during Experimental Autoimmune Encephalomyelitis.
CXCL13 is the major determinant for B cell recruitment to the CSF during neuroinflammation.
Differences in Diffusion Tensor Imaging-Derived Metrics in the Corpus Callosum of Patients With Multiple Sclerosis Without and With Gadolinium-Enhancing Cerebral Lesions.
[Central motor pathways in children with multiple sclerosis].
The Transcription Factor IRF8 Activates Integrin-Mediated TGF-β Signaling and Promotes Neuroinflammation.
Unraveling Natalizumab Effects on Deregulated miR-17 Expression in CD4(+) T Cells of Patients with Relapsing-Remitting Multiple Sclerosis.
Geographical Variations in Sex Ratio Trends over Time in Multiple Sclerosis.
Inpatient Rehabilitation Utilization for Medicare Beneficiaries with Multiple Sclerosis.
Immunomodulators for multiple sclerosis may ameliorate spinal bone loss.
In vivo vs. ex vivo Magnetic Resonance Imaging In Mice.
Potential role of OPG/RANKL system and FokI genotypes in pathogenesis and clinical manifestations in multiple sclerosis.
Quality of Life Assessment in Patients with Multiple Sclerosis Receiving Interferon Beta-1a: A Comparative Longitudinal Study of Avonex and Its Biosimilar CinnoVex.
Assessment of changes in immune measures of multiple sclerosis patients treated with laquinimod.
Pages
« first
‹ previous
…
192
193
194
195
196
197
198
199
200
…
next ›
last »